Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Common Equity (2016 - 2025)

Standard Biotools (LAB) has disclosed Common Equity for 16 consecutive years, with $424.3 million as the latest value for Q4 2025.

  • Quarterly Common Equity fell 10.05% to $424.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $424.3 million through Dec 2025, down 10.05% year-over-year, with the annual reading at $424.3 million for FY2025, 10.05% down from the prior year.
  • Common Equity for Q4 2025 was $424.3 million at Standard Biotools, up from $399.7 million in the prior quarter.
  • The five-year high for Common Equity was $577.3 million in Q1 2024, with the low at -$148.1 million in Q4 2023.
  • Average Common Equity over 5 years is $176.4 million, with a median of $104.4 million recorded in 2021.
  • The sharpest move saw Common Equity plummeted 539.35% in 2023, then skyrocketed 694.23% in 2024.
  • Over 5 years, Common Equity stood at $94.6 million in 2021, then plummeted by 186.12% to -$81.5 million in 2022, then crashed by 81.73% to -$148.1 million in 2023, then skyrocketed by 418.62% to $471.7 million in 2024, then fell by 10.05% to $424.3 million in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at $424.3 million, $399.7 million, and $424.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.